The “Pulmonary Sarcoidosis – Pipeline Insight, 2021” drug pipelines have been added to ResearchAndMarkets.com’s offering.
This “Pulmonary Sarcoidosis – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Pulmonary Sarcoidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Sarcoidosis R&D. The therapies under development are focused on novel approaches for Pulmonary Sarcoidosis.
Pulmonary Sarcoidosis Emerging Drugs Chapters
This segment of the Pulmonary Sarcoidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical, and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pulmonary Sarcoidosis Emerging Drugs
CMK 389: Novartis
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
CMK 389 acts as inhibitors of Interleukin 18. It is being developed by Novartis for Pulmonary sarcoidosis and is currently in the phase II stage of development.
ATYR1923: aTyr Pharma
ATYR1923 is a potential first-in-class, a disease-modifying therapy for patients with severe inflammatory lung diseases with high unmet medical needs. ATYR1923 works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis. ATYR1923 is conducting a Phase 1b/2a clinical trial in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), a group of immune-mediated disorders that cause progressive fibrosis of the lung.
Pulmonary Sarcoidosis: Therapeutic Assessment
This segment of the report provides insights about the different Pulmonary Sarcoidosis drugs segregated based on the following parameters that define the scope of the report, such as:
Major Players working on Pulmonary Sarcoidosis
There are approx. 10+ key companies which are developing Pulmonary Sarcoidosis. The companies which have their Pulmonary Sarcoidosis drug candidates in the most advanced stage, i.e. Phase III include Corbus Pharmaceuticals.
Source: Businesswire
